Research Use Only: Semaglutide, tirzepatide, retatrutide, and cagrilintide are sold exclusively for in vitro and licensed laboratory research. None are approved for human consumption, veterinary use, or therapeutic application. This content is educational and does not constitute medical advice.
Why These Four Compounds Get Compared Together
Semaglutide, tirzepatide, retatrutide, and cagrilintide represent four points on the same research trajectory: incremental expansion of the receptor set being activated in metabolic peptide research. Semaglutide established GLP-1 receptor (GLP-1R) agonism as a validated single-target approach. Tirzepatide added a second receptor (GIP). Retatrutide added a third (glucagon receptor). Cagrilintide took a different route entirely, leaving the incretin receptor set alone and instead pairing GLP-1R agonism with an unrelated hormonal system — the amylin receptor — when studied in combination with semaglutide.
Researchers frequently need to choose among these compounds, or study them side by side, which makes a clear comparison of targets and mechanisms useful reference material. Full individual profiles are available in our semaglutide, tirzepatide, retatrutide, and cagrilintide research overviews.
Receptor Targets at a Glance
- Semaglutide — GLP-1 receptor only. The reference mono-agonist against which multi-receptor compounds are benchmarked.
- Tirzepatide — GLP-1 receptor + GIP receptor. Adds glucose-dependent insulinotropic polypeptide signaling, which independently affects adipose tissue and bone metabolism research endpoints.
- Retatrutide — GLP-1 receptor + GIP receptor + glucagon receptor. The only compound in this group with three active receptor targets, adding energy-expenditure and fat-oxidation research questions on top of the incretin effects shared with tirzepatide.
- Cagrilintide — Amylin receptor (a calcitonin receptor / RAMP heterodimer), structurally unrelated to the incretin receptors above. Studied alone or, more often in current literature, alongside semaglutide as the "CagriSema" combination — see our dedicated CagriSema combination research article.
Mechanistic Differences That Matter for Research Design
The incretin-receptor compounds (semaglutide, tirzepatide, retatrutide) all share a GLP-1R backbone, which means research comparing them is effectively studying what happens as additional receptor targets are layered onto the same foundation. Tirzepatide's added GIP receptor activity has been associated in preclinical models with greater fat-mass reduction and improved insulin sensitivity relative to GLP-1 monoagonism at matched doses. Retatrutide's additional glucagon receptor activity introduces energy-expenditure effects that are mechanistically distinct from anything GLP-1R or GIPR agonism alone produces — glucagon receptor signaling normally raises blood glucose by stimulating hepatic glucose release, but in the context of simultaneous GLP-1R/GIPR activation, research suggests the glucose-raising effect is offset while the fat-oxidation effect persists.
Cagrilintide is the outlier in this group because it does not touch the incretin receptor family at all. Its research relevance comes from testing whether a completely separate satiety pathway — one that signals primarily through brainstem circuits (area postrema, nucleus tractus solitarius) rather than the hypothalamic and gut-based routes GLP-1R and GIPR use — can be additive or synergistic with incretin-receptor agonism rather than redundant with it. Our cagrilintide vs. pramlintide comparison covers how this amylin-analog approach evolved from earlier, shorter-acting research compounds.
Reported Weight-Loss Data From Clinical-Stage Research
For researchers using published clinical trial data as reference points (not as guidance for use outside a regulated protocol), reported weight-reduction figures at maximum studied doses have varied by compound and trial design: semaglutide research has reported mean reductions in roughly the mid-teens percentage range at 2.4 mg dosing; tirzepatide research has reported figures in the low-to-mid 20% range at its highest studied dose; retatrutide's Phase 2 data has been reported in a comparable or higher range depending on dose arm and trial duration; and the semaglutide + cagrilintide combination (CagriSema) reported roughly 20-23% mean weight loss at 68 weeks in its Phase 3 REDEFINE 1 trial, depending on which adherence estimand is used. These figures come from different trial populations, durations, and dosing protocols, so cross-trial comparisons should be treated as directional rather than statistically equivalent. For a deeper dive on any single head-to-head pairing, see our semaglutide vs. tirzepatide and retatrutide vs. tirzepatide comparisons.
Dosing Frequency and Half-Life
All four compounds were engineered for extended half-lives via fatty-acid chain modification, enabling once-weekly subcutaneous administration in the protocols that have studied them — a deliberate design choice that keeps research protocols practically manageable relative to native GLP-1 or native amylin, both of which have half-lives measured in minutes. This shared engineering approach is part of why these four compounds are so often studied and compared as a set rather than in isolation.
Choosing Among These Compounds for a Research Protocol
The right compound for a given research question depends on which receptor pathway the protocol is designed to probe. Studies isolating GLP-1R-specific effects should use semaglutide alone rather than a multi-receptor compound. Studies interested in GIP receptor contributions to adipose or bone endpoints benefit from a tirzepatide-vs-semaglutide comparison arm. Studies probing energy expenditure and glucagon receptor biology are better served by retatrutide. Studies testing whether amylin-pathway co-agonism is additive with incretin agonism require cagrilintide, typically paired with semaglutide. Sourcing guidance for each compound, including COA verification, is available on our where to buy semaglutide, where to buy tirzepatide, and where to buy retatrutide pages.
Frequently Asked Questions
Which of these four compounds has the most receptor targets?
Retatrutide, with activity at the GLP-1, GIP, and glucagon receptors. It is the only triple agonist in this comparison.
Is cagrilintide interchangeable with the other three?
No. Cagrilintide acts on an entirely different receptor system (amylin receptors) and is not a GLP-1-pathway compound, which is why it is typically studied in combination with — rather than instead of — a GLP-1R agonist like semaglutide.
Are any of these approved for human use?
No. All four are sold by V8 Peptides exclusively for licensed laboratory and in vitro research use. Nothing in this article constitutes medical advice.
References
- Novo Nordisk. REDEFINE 1 Phase 3 trial results, obesity/overweight population, 68-week data.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide once weekly for the treatment of obesity." New England Journal of Medicine. 2022;387(3):205-216 (SURMOUNT-1).
- Jastreboff AM, et al. Retatrutide Phase 2 obesity research data. New England Journal of Medicine. 2023.
- Wilding JPH, Batterham RL, Calanna S, et al. "Once-weekly semaglutide in adults with overweight or obesity." New England Journal of Medicine. 2021;384(11):989-1002 (STEP 1).
Written and reviewed by the V8 Peptides Research Team. All compounds referenced are sold for research purposes only. Nothing in this article constitutes medical advice or a recommendation for human use.
Related reading: CagriSema Combination Research · GLP-1 Receptor Agonists in Research · Semaglutide & Tirzepatide Buyer's Guide